- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03588936
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Phase 1 Study of Nivolumab in Combination With Tocilizumab for Treatment of Patients With Relapsed Hematological Malignancies Post-allogeneic Transplant
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
Study disease: Hematologic malignancies including, but not exclusive to,acute/chronic leukemia, lymphoma, and myelodysplastic syndrome that has relapsed after allogeneic transplant.
Study Rationale: Phase 1 Safety/Dose Finding Study: To determine the safety and maximum tolerated dose of Nivolumab in combination with Tocilizumab.
Study Agent Description:
Tocilizumab is a monoclonal antibody and immunosuppressant; specifically, tocilizumab is an IL-6 receptor antagonist.
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor of T cells blocking its interaction with PD-L1 and PD-L2, thereby enhancing T-cell proliferation and allowing the immune system to attack the tumor.
Number of Subjects: A maximum of 12 participants will be enrolled on this Phase 1 study.
Duration of Follow-up: Participants will be followed for up to one year post-treatment for survival and response.
Study Design: This is a 3 + 3 design. In a "3 + 3 design," three participants are initially enrolled into a given dose cohort. If there is no dose limiting toxicity (DLT) observed in any of these subjects, the trial proceeds to enroll additional subjects into the next higher dose cohort. If one subject develops a DLT at a specific dose, an additional three subjects are enrolled into that same dose cohort. Development of DLTs in more than one of six subjects in a specific dose cohort suggests that the maximum tolerated dose (MTD) has been exceeded, and further dose escalation is not pursued.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Froedtert Hospital and the Medical College of Wisconsin
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria
- Age≥18 years with hematological malignancies who have undergone allogeneic transplant for hematological malignancy and are ≥180 days post-transplant.
- Relapsed disease post-allogeneic transplant defined as follows i. Acute or Chronic Leukemia or myelodysplastic or myeloproliferative disorders or natural killer (NK) cell neoplasms: Bone marrow (BM) with ≥5% disease involvement or peripheral blood evidence of overt relapse ii. Lymphoma: BM evidence of relapsed/persistent disease or PET/CT or CT evidence of persistent/progressive lymphadenopathy consistent with active lymphoma. Active disease defined as nodal lesions ≥ 20 mm in the long axis or extranodal lesions≥10 mm in long and short axis or bone marrow involvement that is biopsy proven
- Karnofsky performance status ≥70 (See Appendix A for details)
- Creatinine Clearance≥60 ml/min
- Adequate hepatic function, defined as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 x upper limit of normal (ULN). Serum bilirubin and alkaline phosphatase ≤3x x ULN, or considered not clinically significant (e.g. Gilbert's or indirect hyperbilirubinemia) or felt to be due to underlying disease.
- Without evidence of active acute or chronic graft versus host disease (GVHD)
- Off all immunosuppression and corticosteroids (other than replacement dose steroids defined as equivalent to a maximum of 10 mg Prednisone daily) for ≥28 days from first treatment.
- Off all disease targeted treatments for ≥10 days to first treatment day
- Able to provide written informed consent
- Women of child-bearing potential and men must agree to use adequate contraception for the duration of study participation and for 120 days after the last treatment with nivolumab.
- No FDA approved, more appropriate therapies available for disease control as determined by the treating physician
Exclusion Criteria
- Positive beta-human chorionic gonadotropin (HCG) in female of child-bearing potential
- Cluster of differentiation 3 (CD3) donor chimerism <5% within 4 weeks of starting study treatment
- Prior administration of donor lymphocyte infusion post-allogeneic transplant within the last 6 months of study treatment
- History of or active autoimmune disease, or other syndrome that requires systemic steroids.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab.
- Uncontrolled or active infections on treatment
- Confirmed active human immunodeficiency virus (HIV), Hepatitis B or C infection.
- Presence of ≥grade 3 non-hematologic toxicities as per CTCAE version 5 from any previous treatment unless it is felt to be due to underlying disease.
Concurrent use of investigational therapeutic agents or enrollment on another therapeutic clinical trial at any institution.
a. Minimum of 4 weeks from last dose of investigational agent
- Prior exposure to PD-1 or CTLA4 antibodies in the post-allogeneic transplant setting. Participants who received such agents pre-allogeneic transplant will NOT be excluded.
- Prior exposure to daratumumab in the post-allogeneic transplant setting within two months of start date of treatment with this investigational protocol. Participants who received this agent pre-allogeneic transplant will NOT be excluded
- Concurrent therapies targeted at disease relapse. However, previous treatments for relapsed disease are allowed.
- Concurrent active malignancy (exceptions: treated solid malignancy in >2 years' remission, treated basal or squamous cell carcinomas of the skin)
- History of Crohn's disease or ulcerative colitis
- History of demyelinating disorder
- Prior intolerance or allergy to tocilizumab
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Nivolumab (0.25 mg/kg) and Tocilizumab
Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.25 mg/kg based on dose escalation design). Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab. |
Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
Altri nomi:
Participants will receive 2 doses of tocilizumab
Altri nomi:
|
Sperimentale: Nivolumab (0.5 mg/kg) and Tocilizumab
Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.5 mg/kg based on dose escalation design). Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab. |
Participants will receive 2 doses of tocilizumab
Altri nomi:
Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Maximum-tolerated Dose
Lasso di tempo: Up to 4 weeks after last dose of study treatment (approximately 3 months)
|
Determine the safety and the maximum tolerated dose among two candidate doses of nivolumab in combination with tocilizumab for treatment of relapsed hematological malignancy post-allogeneic transplant.
Maximum-tolerated dose is based on the determination of dose-limiting toxicities.
|
Up to 4 weeks after last dose of study treatment (approximately 3 months)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Response Rates Based on Imaging
Lasso di tempo: End of study treatment (approximately 2 months)
|
The number of subjects with stable disease as evidenced by imaging (Diagnostic positron emission tomography (PET)-CT scans or CT of the neck, chest, abdomen, and pelvis).
|
End of study treatment (approximately 2 months)
|
Response Rates Based on Pathologic Response
Lasso di tempo: End of study treatment (approximately 2 months)
|
The number of subjects with bone marrow response (achievement of complete response; <5% blasts; stable disease; progressive disease).
|
End of study treatment (approximately 2 months)
|
Overall Survival
Lasso di tempo: Up to 1 year from beginning of treatment
|
The number of participants alive.
|
Up to 1 year from beginning of treatment
|
Progression-Free Survival
Lasso di tempo: Up to 1 year from beginning of treatment
|
Determine the number of subjects alive and in remission after treatment.
|
Up to 1 year from beginning of treatment
|
Duration of response in responding participants
Lasso di tempo: Up to 1 year from the beginning of treatment
|
Number of subjects with complete response or stable disease.
|
Up to 1 year from the beginning of treatment
|
Dose-limiting toxicities
Lasso di tempo: Up to 4 weeks after last dose of study treatment (approximately 3 months)
|
The number of subjects with dose-limiting toxicities.
This will be measured by the number of adverse events as defined by the NCI CTCAE version 4.03 non-hematologic ≥ grade 3-5 signs/symptoms or by the development of steroid refractory grade 2-4 graft-versus-host disease or severe chronic graft-versus-host disease.
|
Up to 4 weeks after last dose of study treatment (approximately 3 months)
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Nirav Shah, MD, Medical College of Wisconsin
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per tipo istologico
- Neoplasie
- Neoplasie per sede
- Malattie del midollo osseo
- Malattie ematologiche
- Sindromi mielodisplastiche
- Neoplasie ematologiche
- Leucemia
- Meccanismi molecolari dell'azione farmacologica
- Agenti antineoplastici
- Agenti antineoplastici, immunologici
- Inibitori del checkpoint immunitario
- Nivolumab
Altri numeri di identificazione dello studio
- PRO32525
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Nivolumab (.25 mg/kg)
-
Bristol-Myers SquibbCompletatoMelanomaFrancia, Canada, Stati Uniti, Germania, Australia, Federazione Russa, Spagna, Italia, Olanda, Polonia, Danimarca, Israele, Regno Unito
-
Michael B. Atkins, MDBristol-Myers Squibb; Hoosier Cancer Research NetworkAttivo, non reclutanteCarcinoma a cellule renali avanzatoStati Uniti
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.TerminatoGlioblastoma ricorrenteStati Uniti
-
United BioPharmaNational Taiwan University Hospital; Kaohsiung Medical University Chung-Ho Memorial... e altri collaboratoriCompletatoInfezione da HIV-1Taiwan
-
UBP Greater China (Shanghai) Co., LtdNon ancora reclutamento
-
Dana-Farber Cancer InstituteBristol-Myers SquibbReclutamento
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbReclutamentoCancro della vescica urinaria | Cancro invasivo della vescicaOlanda
-
Shanghai Junshi Bioscience Co., Ltd.Completato
-
University of Sao Paulo General HospitalReclutamentoDisfunsione dell'arteria coronaria | Diabete mellito, tipo 2 | Danno renale acuto | Chirurgia di bypass delle arterie coronarieBrasile
-
AO GENERIUMCompletato